Deal-Making

Ipsen will use Marengo Therapeutics’ TriSTAR precision T-cell engager (TCE) platform to bolster selective Vβ T-cells to boost anti-tumor activity in difficult-to-treat ‘cold’ tumors.

Deal Making

Essential Pharma has partnered with AGC Biologics to manufacture its clinical mAb candidate to treat high-risk neuroblastoma (HRNB).

Facilities & Capacity

Merck KGaA has expanded its MilliporeSigma life sciences business at its global headquarters in Darmstadt, Germany, and has nearly doubled capacity at its Schnelldorf site.

Facilities & Capacity

Kyowa Kirin is breaking ground on its first North American facility in Sanford, North Carolina to produce antibodies for debilitating diseases.

Global Markets

WuXi Biologics’ share price spiked after the BIOSECURE Act failed to make the House Rules Committee’s list of floor amendments to the fiscal 2025 National Defense Authorization Act (NDAA).

Global Markets

While emerging technologies are “exceptional,” GSK says we cannot keep adding innovation to a system that is beyond sustainable capacity.

Regulations

WuXi Biologics’ share price spiked after the BIOSECURE Act failed to make the House Rules Committee’s list of floor amendments to the fiscal 2025 National Defense Authorization Act (NDAA).

Regulations

Independent advisors to the US Food and Drug Administration (FDA) have deemed the benefits of Eli Lilly’s Alzheimer’s drug donanemab (LY3002813) outweigh the risks.

Therapeutic Class

ScaleReady, in collaboration with Wilson Wolf, Bio-Techne, and CellReady, has launched a ‘G-Rex’ grant program aimed at advancing CGTs. We spoke to ScaleReady’s CEO to find out more.

Therapeutic Class

The US National Institute of Health (NIH) will fund Pluri’s potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).

Upstream & Downstream Processing

Novo Holdings, the investment company behind pharma giant Novo Nordisk, will acquire a controlling stake in bioprocess fluid management firm Single Use Support.

Upstream & Downstream Processing

Repligen says it is looking at new modalities and its filtration franchise to drive momentum following a mixed first quarter 2024.